74 related articles for article (PubMed ID: 12687275)
1. P53 and C-FOS overexpression in patients with thyroid cancer: an immunohistochemical study.
Kataki A; Sotirianakos S; Memos N; Karayiannis M; Messaris E; Leandros E; Manouras A; Androulakis G
Neoplasma; 2003; 50(1):26-30. PubMed ID: 12687275
[TBL] [Abstract][Full Text] [Related]
2. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
3. Maspin in thyroid cancer: its relationship with p53 and clinical outcome.
Boltze C; Schneider-Stock R; Meyer F; Peters B; Quednow C; Hoang-Vu C; Roessner A
Oncol Rep; 2003; 10(6):1783-7. PubMed ID: 14534696
[TBL] [Abstract][Full Text] [Related]
4. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
5. c-Met expression in tall cell variant papillary carcinoma of the thyroid.
Nardone HC; Ziober AF; LiVolsi VA; Mandel SJ; Baloch ZW; Weber RS; Mick R; Ziober BL
Cancer; 2003 Oct; 98(7):1386-93. PubMed ID: 14508824
[TBL] [Abstract][Full Text] [Related]
6. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer.
Granja F; Morari J; Morari EC; Correa LA; Assumpção LV; Ward LS
Cancer Lett; 2004 Jul; 210(2):151-7. PubMed ID: 15183530
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
Omar E; Madhavan M; Othman NH
Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
9. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
10. [Transgenic models of human thyroid pathologies: hyperfunctional adenoma, anaplastic cancer, differentiated cancer, hypothyroidism].
Ledent C
Bull Mem Acad R Med Belg; 1996; 151(2):195-201. PubMed ID: 9004925
[TBL] [Abstract][Full Text] [Related]
11. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers.
Wang JY; Hsieh JS; Chen CC; Tzou WS; Cheng TL; Chen FM; Huang TJ; Huang YS; Huang SY; Yang T; Lin SR
J Surg Res; 2004 Aug; 120(2):242-8. PubMed ID: 15234219
[TBL] [Abstract][Full Text] [Related]
12. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma.
Weinberger PM; Adam BL; Gourin CG; Moretz WH; Bollag RJ; Wang BY; Liu Z; Lee JR; Terris DJ
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):503-10. PubMed ID: 17515507
[TBL] [Abstract][Full Text] [Related]
13. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature.
Wada N; Yoshida A; Miyagi Y; Yamamoto T; Nakayama H; Suganuma N; Matsuzu K; Masudo K; Hirakawa S; Rino Y; Masuda M; Imada T
Anticancer Res; 2008; 28(1A):139-44. PubMed ID: 18383837
[TBL] [Abstract][Full Text] [Related]
15. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
[TBL] [Abstract][Full Text] [Related]
16. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
17. [Role of the class II tumor suppressor gene maspin in thyroid carcinogenesis].
Boltze C; Hoang-Vu C; Schneider-Stock R; Lehnert H; Roessner A
Verh Dtsch Ges Pathol; 2004; 88():237-45. PubMed ID: 16892558
[TBL] [Abstract][Full Text] [Related]
18. Expression of the GLUT1 glucose transporter, p63 and p53 in thyroid carcinomas.
Kim YW; Do IG; Park YK
Pathol Res Pract; 2006; 202(11):759-65. PubMed ID: 17029809
[TBL] [Abstract][Full Text] [Related]
19. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
